Key features and details
- Rabbit polyclonal to IFN gamma Receptor beta/AF-1 - C-terminal
- Suitable for: WB, Flow Cyt, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-IFN gamma Receptor beta/AF-1 antibody - C-terminal
See all IFN gamma Receptor beta/AF-1 primary antibodies
DescriptionRabbit polyclonal to IFN gamma Receptor beta/AF-1 - C-terminal
Tested applicationsSuitable for: WB, Flow Cyt, IHC-Pmore details
Species reactivityReacts with: Human
Synthetic peptide within Human IFN gamma Receptor beta/AF-1 aa 308-337 (C terminal) conjugated to keyhole limpet haemocyanin. The exact sequence is proprietary.
Database link: P38484
- MDA-MB453 cell lysate; Human lung carcinoma tissue; NCA-H292 cells.
Previously labelled as IFN gamma Receptor beta.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: 99% PBS
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab175878 is purified through a protein A column, followed by peptide affinity purification.
Our Abpromise guarantee covers the use of ab175878 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Predicted molecular weight: 38 kDa.|
|Flow Cyt||1/10 - 1/50.
ab171870 - Rabbit polyclonal IgG, is suitable for use as an isotype control with this antibody.
|IHC-P||1/50 - 1/100. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionPart of the receptor for interferon gamma. Required for signal transduction. This accessory factor is an integral part of the IFN-gamma signal transduction pathway and is likely to interact with GAF, JAK1, and/or JAK2.
Involvement in diseaseDefects in IFNGR2 are a cause of mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]; also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity, whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance.
Sequence similaritiesBelongs to the type II cytokine receptor family.
Contains 2 fibronectin type-III domains.
- Information by UniProt
- AF 1 antibody
- AF-1 antibody
- AF1 antibody
Flow cytometric analysis of NCI-H292 cells labeling IFN gamma Receptor beta/AF-1 with ab175878 at 1/10 dilution (bottom histogram) compared to a negative control cell (top histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human lung carcinoma tissue labeling IFN gamma Receptor beta/AF-1 with ab175878 at 1/50 dilution followed by peroxidase conjugation of the secondary antibody and DAB staining.
Anti-IFN gamma Receptor beta/AF-1 antibody - C-terminal (ab175878) at 1/1000 dilution + MDA-MB453 cell lysate at 35 µg
Predicted band size: 38 kDa
ab175878 has been referenced in 4 publications.
- Xiao F et al. Sex-dependent aortic valve pathology in patients with rheumatic heart disease. PLoS One 12:e0180230 (2017). IHC-P ; Human . PubMed: 28662157
- Iskandar R et al. Expression of pericardial fluid T-cells and related inflammatory cytokines in patients with chronic heart failure. Exp Ther Med 13:1850-1858 (2017). PubMed: 28565777
- Cai C et al. Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma. Exp Ther Med 14:3221-3228 (2017). PubMed: 28912872
- Pickering AM et al. Lifespan of mice and primates correlates with immunoproteasome expression. J Clin Invest 125:2059-68 (2015). PubMed: 25866968